Stock Analysis on Net

Danaher Corp. (NYSE:DHR)

$24.99

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Profitability Ratios (Summary)

Danaher Corp., profitability ratios (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Return on Sales
Gross profit margin
Operating profit margin
Net profit margin
Return on Investment
Return on equity (ROE)
Return on assets (ROA)

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).


The profitability metrics exhibited varied trends over the observed period. Generally, a decline in profitability is apparent across most ratios from early 2022 through the end of 2025, although some fluctuations occur within that overall trend.

Gross Profit Margin
The gross profit margin demonstrated relative stability in the initial periods, fluctuating around 60.7% to 60.2% from April 2022 to December 2022. A gradual downward trend commenced in early 2023, reaching approximately 58.4% by March 2024. The margin experienced minor recoveries in the subsequent quarters, peaking at 59.7% in March 2025, before concluding at 59.1% in December 2025. The overall decline, while moderate, suggests potential pressures on cost of goods sold or pricing strategies.
Operating Profit Margin
The operating profit margin initially increased from 25.2% in April 2022 to a peak of 27.6% in December 2022. A more pronounced decline followed, with the margin decreasing to 21.7% by December 2023 and further to 19.1% by December 2025. This suggests increasing operating expenses relative to revenue, or a weakening of the company’s core operational efficiency. The largest single drop occurred between September 2023 and December 2023.
Net Profit Margin
Similar to the operating margin, the net profit margin peaked at 22.9% in December 2022 before experiencing a consistent decline. By December 2025, the net profit margin had fallen to 14.7%. This decrease is likely influenced by both the operating margin decline and potential changes in non-operating items such as interest expense or taxes. The rate of decline accelerated in the latter half of the observed period.
Return on Equity (ROE)
The return on equity followed a similar trajectory to the profit margins, decreasing from 13.9% in April 2022 to 6.9% in September 2025, and slightly recovering to 6.9% in December 2025. This indicates a diminishing ability to generate profits from shareholder investments. The decline in ROE mirrors the decline in net income and potentially reflects changes in the company’s capital structure.
Return on Assets (ROA)
The return on assets also exhibited a downward trend, decreasing from 7.7% in April 2022 to 4.3% in December 2025. This suggests a decreasing efficiency in utilizing assets to generate profits. The ROA decline is consistent with the observed declines in profitability and asset turnover. The most significant decrease occurred between September 2023 and December 2025.

In summary, the observed period demonstrates a consistent erosion of profitability metrics. While the gross profit margin experienced some stability, the operating, net, ROE, and ROA all showed clear downward trends, indicating increasing challenges in maintaining profitability and efficiently utilizing resources.


Return on Sales


Return on Investment


Gross Profit Margin

Danaher Corp., gross profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data (US$ in millions)
Gross profit
Sales
Profitability Ratio
Gross profit margin1
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q4 2025 Calculation
Gross profit margin = 100 × (Gross profitQ4 2025 + Gross profitQ3 2025 + Gross profitQ2 2025 + Gross profitQ1 2025) ÷ (SalesQ4 2025 + SalesQ3 2025 + SalesQ2 2025 + SalesQ1 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The gross profit margin exhibited relative stability over the observed period, generally fluctuating between 58.39% and 60.77%. Initial values demonstrated consistency, followed by a period of moderate decline and subsequent stabilization before a slight decrease towards the end of the period.

Initial Period (Apr 1, 2022 – Dec 31, 2022)
The gross profit margin began at 60.77% and remained at that level for the first two quarters. A slight decrease was then observed, moving from 60.77% to 60.21% by the end of December 2022. This initial period indicates a strong and consistent profitability in relation to sales.
Period of Decline (Mar 31, 2023 – Sep 29, 2023)
A more noticeable downward trend emerged in the first half of 2023, with the gross profit margin declining from 60.22% to 58.77%. This decline continued through September 29, 2023, reaching 58.77%. This period suggests potential pressures on cost of goods sold or pricing strategies.
Stabilization and Subsequent Fluctuation (Dec 31, 2023 – Jun 28, 2025)
Following the decline, the gross profit margin stabilized around the 59% mark, fluctuating between 58.39% and 59.66% for several quarters. A slight increase to 59.74% was observed in March 2024, followed by a return to the 59% range. The most recent period shows a slight decrease to 59.11% by December 2025. This suggests a period of adaptation and potential cost management efforts, though recent results indicate a renewed, albeit small, downward pressure.

Overall, the gross profit margin demonstrates resilience, maintaining a generally high level throughout the analyzed timeframe. While fluctuations exist, the margin has largely remained within a narrow band, indicating a consistent ability to control production costs and maintain pricing power. The slight decline observed in the most recent quarter warrants further investigation to determine its underlying causes and potential implications.


Operating Profit Margin

Danaher Corp., operating profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data (US$ in millions)
Operating profit
Sales
Profitability Ratio
Operating profit margin1
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q4 2025 Calculation
Operating profit margin = 100 × (Operating profitQ4 2025 + Operating profitQ3 2025 + Operating profitQ2 2025 + Operating profitQ1 2025) ÷ (SalesQ4 2025 + SalesQ3 2025 + SalesQ2 2025 + SalesQ1 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The operating profit margin exhibited a generally declining trend over the observed period, although with some fluctuations. Initially strong, the margin subsequently moderated, demonstrating a potential shift in the company’s operational efficiency or pricing power.

Initial Performance (Apr 1, 2022 – Dec 31, 2022)
The operating profit margin began at 25.23% and peaked at 27.61% by the end of 2022. This period indicates a robust level of profitability, with consistent margins above 25%. A slight increase is observed from the first to the fourth quarter of 2022, suggesting positive momentum during that timeframe.
Moderation and Decline (Mar 31, 2023 – Dec 31, 2024)
Starting in the first quarter of 2023, a noticeable decline in the operating profit margin commenced. The margin decreased from 27.02% to 20.37% by the end of 2024. This represents a significant reduction in profitability over two years. Fluctuations occurred within this period, with a low of 18.39% in the second quarter of 2025, but the overall trend remained downward.
Recent Stabilization (Mar 28, 2025 – Dec 31, 2025)
The final two quarters of the observed period show a slight stabilization, with the operating profit margin increasing from 18.39% to 19.09%. While still lower than the levels seen in 2022, this suggests a potential bottoming out of the decline. However, further observation is needed to confirm a sustained recovery.
Correlation with Sales
A review of sales figures alongside the operating profit margin reveals that declines in margin do not consistently correlate with declines in sales. For example, sales increased from $7,688 million to $8,369 million between April 2022 and December 2022, while the operating profit margin remained relatively stable. Conversely, sales decreased from $6,405 million to $5,796 million between September 2023 and March 2024, while the operating profit margin experienced a smaller decline. This suggests factors beyond revenue volume are influencing profitability.

In summary, the operating profit margin experienced a period of strength followed by a sustained decline, with a potential for stabilization in the most recent quarters. The relationship between sales and margin is not straightforward, indicating that cost management, pricing strategies, or product mix shifts likely play a significant role in the observed trends.


Net Profit Margin

Danaher Corp., net profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data (US$ in millions)
Net earnings
Sales
Profitability Ratio
Net profit margin1
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q4 2025 Calculation
Net profit margin = 100 × (Net earningsQ4 2025 + Net earningsQ3 2025 + Net earningsQ2 2025 + Net earningsQ1 2025) ÷ (SalesQ4 2025 + SalesQ3 2025 + SalesQ2 2025 + SalesQ1 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The net profit margin exhibited fluctuations over the analyzed period, spanning from April 2022 to December 2025. Initially, the metric demonstrated relative stability in the early quarters, followed by a discernible downward trend in later periods.

Initial Stability & Peak (Apr 1, 2022 – Dec 31, 2022)
The net profit margin began at 21.32% and fluctuated between 20.61% and 22.91% during this timeframe. The highest value within the observed period, 22.91%, was recorded on December 31, 2022, suggesting strong profitability at the end of the year. This initial period indicates a consistent ability to translate sales into profit.
Moderate Decline (Mar 31, 2023 – Dec 31, 2023)
From March 31, 2023, a gradual decline commenced. The net profit margin decreased from 23.32% to 19.94% by December 31, 2023. While still representing a healthy margin, this period signals a weakening in profitability compared to the prior year.
Accelerated Downward Trend (Mar 29, 2024 – Jun 27, 2025)
The rate of decline accelerated in the subsequent quarters. The net profit margin fell from 18.54% in March 2024 to a low of 14.21% in June 2025. This represents a significant contraction in profitability, potentially indicating increased costs, pricing pressures, or shifts in the sales mix.
Partial Recovery (Sep 26, 2025 – Dec 31, 2025)
A slight recovery was observed in the final two quarters. The net profit margin increased to 14.43% in September 2025 and further to 14.71% in December 2025. However, this recovery did not return the metric to the levels observed in the earlier part of the analyzed period.

Overall, the trend suggests a deterioration in profitability over the analyzed timeframe. While fluctuations occurred, the general direction points towards a decreasing ability to convert sales into net earnings. Further investigation into the underlying drivers of these changes, such as cost of goods sold, operating expenses, and pricing strategies, would be necessary to fully understand the observed trends.


Return on Equity (ROE)

Danaher Corp., ROE calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data (US$ in millions)
Net earnings
Total Danaher stockholders’ equity
Profitability Ratio
ROE1
Benchmarks
ROE, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q4 2025 Calculation
ROE = 100 × (Net earningsQ4 2025 + Net earningsQ3 2025 + Net earningsQ2 2025 + Net earningsQ1 2025) ÷ Total Danaher stockholders’ equity
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The Return on Equity (ROE) exhibited a generally declining trend over the observed period, beginning in April 2022 and continuing through December 2025. Initial values were relatively stable, followed by a more pronounced decrease in the latter half of the period.

Initial Period (Apr 1, 2022 – Dec 31, 2022)
ROE values fluctuated within a narrow range, starting at 13.93% and remaining above 13.60% throughout the period. A slight increase was observed from April to September 2022 (13.93% to 14.40%), followed by a minor decrease to 14.39% by the end of the year. This suggests a period of relative stability in profitability relative to equity.
Declining Trend (Mar 31, 2023 – Dec 31, 2024)
A consistent downward trend in ROE became apparent starting in March 2023. The ratio decreased from 13.47% to 8.91% by December 2024. This decline indicates a weakening in the company’s ability to generate profit from shareholder investments. The rate of decline accelerated during this period.
Stabilization and Slight Recovery (Mar 28, 2025 – Dec 31, 2025)
The rate of decline slowed in the final quarters of the observed period. ROE reached a low of 6.52% in June 2025, then experienced a modest increase to 6.86% in September 2025 and 6.88% in December 2025. While still significantly lower than initial values, this suggests a potential stabilization of profitability relative to equity, although further observation is needed to confirm a sustained recovery.
Net Earnings and Equity Relationship
The decline in ROE appears to be driven by a combination of factors. While net earnings decreased over the period, total stockholders’ equity generally increased. The larger increase in equity, relative to the decrease in net earnings, contributed to the overall reduction in ROE. Specifically, the most significant drop in ROE coincided with periods of lower net earnings and continued growth in stockholders’ equity.

In summary, the company experienced a notable decrease in ROE over the analyzed timeframe. The initial stability gave way to a consistent decline, with a potential for stabilization emerging in the most recent quarters. The interplay between net earnings and equity growth appears to be a key driver of this trend.


Return on Assets (ROA)

Danaher Corp., ROA calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 26, 2025 Jun 27, 2025 Mar 28, 2025 Dec 31, 2024 Sep 27, 2024 Jun 28, 2024 Mar 29, 2024 Dec 31, 2023 Sep 29, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jul 1, 2022 Apr 1, 2022
Selected Financial Data (US$ in millions)
Net earnings
Total assets
Profitability Ratio
ROA1
Benchmarks
ROA, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).

1 Q4 2025 Calculation
ROA = 100 × (Net earningsQ4 2025 + Net earningsQ3 2025 + Net earningsQ2 2025 + Net earningsQ1 2025) ÷ Total assets
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The Return on Assets (ROA) exhibited a generally declining trend over the analyzed period, spanning from April 1, 2022, to December 31, 2025. Initial values demonstrated a relatively stable performance, followed by a noticeable decrease in later periods.

Initial Performance (Apr 1, 2022 – Dec 31, 2022)
The ROA began at 7.74% and experienced a slight increase to 7.76% in the subsequent quarter. A further increase was observed, reaching 8.35% and peaking at 8.55% by December 31, 2022. This initial period indicates a strong and improving ability to generate earnings from its asset base.
Transitional Phase (Mar 31, 2023 – Jun 30, 2023)
Following the peak, the ROA decreased to 8.15% in the March 2023 quarter and continued its downward trajectory to 7.49% by June 30, 2023. This suggests a potential weakening in the efficiency of asset utilization or a decline in profitability during this period.
Accelerated Decline (Sep 29, 2023 – Dec 31, 2024)
The rate of decline accelerated in the latter half of 2023 and into 2024. The ROA fell from 6.74% in September 2023 to 5.64% by December 2023, and continued to decrease, reaching 5.03% by December 2024. This period represents a significant reduction in the return generated from the company’s assets.
Stabilization and Slight Recovery (Mar 28, 2025 – Dec 31, 2025)
The decline appeared to moderate in the first half of 2025, with the ROA fluctuating between 4.76% and 4.18%. A slight recovery was observed in the final two quarters, with the ROA reaching 4.38% in September 2025 and 4.33% by December 31, 2025. While still lower than the initial values, this suggests a potential stabilization of asset utilization efficiency.

Overall, the trend indicates a diminishing capacity to generate profits from the asset base over the analyzed timeframe. While a slight stabilization is noted towards the end of the period, the ROA remains considerably lower than its initial levels. Further investigation into the underlying factors driving these changes, such as shifts in net earnings, asset composition, or operational efficiency, would be necessary to fully understand the observed trends.